Table 2

Treatment-emergent adverse events reported in ≥2% of patients in the overall safety population or treatment-naïve subgroup

Treatment-emergent adverse events, n (%)Overall population (N=196)Treatment-naïve subgroup (N=55)
Total108 (55.1)45 (81.8)
 Treatment related45 (23.0)14 (25.5)
  Serious*1 (0.5)0
Increase in intraocular pressure†38 (19.4)11 (20.0)
Conjunctival haemorrhage8 (4.1)2 (3.6)
Vitreous haemorrhage5 (2.6)1 (1.8)
Influenza5 (2.6)1 (1.8)
Fall5 (2.6)1 (1.8)
Eye irritation4 (2.0)1 (1.8)
Macular hole2 (1.0)2 (3.6)
Diabetic ulcer2 (1.0)2 (3.6)
  • *Increase in intraocular pressure from baseline.

  • †Compared with baseline.